Robert D. Beckett

Robert D. Beckett

Auto-generated profile, based on publicly available information

Robert D. Beckett

Manchester University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2014 in Health Information and Libraries Journal
Verified
Journal Article
Closed access
PDF file
RBRachel Buchanan
Rachel Buchanan
RBRobert D. Beckett
Robert D. Beckett

2 November 2011 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
RBRobert D. Beckett
Robert D. Beckett
CCChristopher W. Crank
Christopher W. Crank
AWAnn Wehmeyer
Ann Wehmeyer
Purpose: Pharmacists have been shown to improve medication reconciliation at hospital admission. Limited resources may obligate pharmacy departments to target resources for medication reconciliation rather than extend services to the entire hospital. We conducted a prospective, randomized, nonblinded assessment of the effectiveness and feasibility of pharmacist-led admission medication reconciliation for geriatric patients. Methods: Eighty-one geriatric patients were randomized 1:1 to receive medication reconciliation per current hospital practice or to pharmacist-led medication reconciliation at admission. The primary end point was medication profile appropriateness by pharmacist review at 48 hours postadmission. Secondary end points involved in determining the impact and feasibility of this program. Results: Pharmacist-led medication was superior to standard hospital practice, with 48% of controls and 71% of intervention patients having appropriate medication profiles at 48 hours postadmission (P = .033). Pharmacists identified 116 discrepancies among 81 patients including predominantly omissions (41%) and a composite of wrong dose, route, or frequency (35%). Pharmacists spent a median 15 minutes per patient. Conclusion: Pharmacists improved admission medication reconciliation for geriatric patients. Pharmacists identified a significant number of discrepancies, including predominantly omissions and wrong dose, dosage form, or frequency. Pharmacists’ contributions to medication reconciliation could yield substantial benefit to patient care.

23 June 2016 in Journal of Evidence-Based Complementary & Alternative Medicine
Verified
Journal Article
Open access
KPKimberly Perkins
Kimberly Perkins
WSWilliam Sahy
William Sahy
RBRobert D. Beckett
Robert D. Beckett
The objective of this review is to identify, summarize, and evaluate clinical trials to determine the efficacy of curcuma in the treatment of osteoarthritis. A literature search for interventional studies assessing efficacy of curcuma was performed, resulting in 8 clinical trials. Studies have investigated the effect of curcuma on pain, stiffness, and functionality in patients with knee osteoarthritis. Curcuma-containing products consistently demonstrated statistically significant improvement in osteoarthritis-related endpoints compared with placebo, with one exception. When compared with active control, curcuma-containing products were similar to nonsteroidal anti-inflammatory drugs, and potentially to glucosamine. While statistical significant differences in outcomes were reported in a majority of studies, the small magnitude of effect and presence of major study limitations hinder application of these results. Further rigorous studies are needed prior to recommending curcuma as an effective alternative therapy for knee osteoarthritis.

16 January 2017 in Journal of Evidence-Based Complementary & Alternative Medicine
Verified
Journal Article
Open access
LKLaura M. Koppen
Laura M. Koppen
AWAndrea Whitaker
Andrea Whitaker
ARAudrey Rosene
Audrey Rosene
RBRobert D. Beckett
Robert D. Beckett
The objective of this review is to identify, summarize, and evaluate clinical trials of berberine for the treatment of hyperlipidemia and other dyslipidemias. A literature search for randomized, controlled trials of berberine that assessed at least 2 lipid values as endpoints resulted in identification of 12 articles that met criteria. The majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL). Common study limitations included lack of reporting of precision in their endpoints, description of blinding, transparency in flow of patients, and reporting of baseline concomitant medications. Berberine could serve as an alternative for patients who are intolerant to statins, patients resistant to starting statin therapy but who are open to alternative treatments, and for low-risk patients not indicated for statin therapy.

1 July 2022 in American Journal of Pharmaceutical Education
Verified
Journal Article
Open access
PDF file
KFKaren S. Fiano
Karen S. Fiano
OAOmar Attarabeen
Omar Attarabeen
JAJill M. Augustine
Jill M. Augustine
RBRobert D. Beckett
Robert D. Beckett
CGCarol S. Goldin
Carol S. Goldin
JSJulie M. Sease
Julie M. Sease
Objective. The objectives of this study were to 1) describe characteristics of NAPLEX preparation programs currently utilized by colleges and schools of pharmacy and 2) to evaluate these program characteristics in relation to first-time NAPLEX pass rates. Methods. This cross-sectional study was based on an online survey administered between February and March 2020. Assessment leads from 143 PharmD programs were invited to answer questions on their schools’ PharmD program characteristics and various aspects of NAPLEX preparation programs. The study included regression analyses to investigate the associations between the NAPLEX first-attempt pass rates and PharmD demographic characteristics, as well as data collection on various aspects of the NAPLEX preparation programs. Finally, common themes from the open-ended questions were identified. Results. Fifty-eight participants completed the survey out of 132 successfully delivered email invitations (response rate = 44%). Fifty participants (86%) indicated that their PharmD program offers a NAPLEX preparation program. Our data indicate that offering a NAPLEX preparation program was not significantly associated with higher NAPLEX first-attempt pass rates. The analysis identified possible explanations for this lack of association, including student concerns with balancing a prep program with APPEs, and faculty workload associated with delivering such programs. Conclusion. The current findings show no association between offering a NAPLEX preparation program and NAPLEX first attempt pass rate. Future research should continue to examine the impact of these programs on individual school pass rates and factors that may enhance student motivation to engage in these programs.

31 December 2022 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PGPaige M. Grube
Paige M. Grube
RBRobert D. Beckett
Robert D. Beckett
The oral sodium-glucose cotransporter 2 inhibitor, dapagliflozin, is used to treat kidney disease, heart failure, and diabetes in adults, but has not been well studied in pediatrics, and does not have a recognized place in therapy in current practice guidelines. The purpose of this review is to summarize studies that have investigated the efficacy of dapagliflozin in pediatric patients. A systematic review was performed to identify clinical studies of oral dapagliflozin in children 0 to 17 years. Studies were identified through searches of Scopus, Web of Science, PubMed, Google Scholar, Embase, clinical trial registries, research registries, and key journals through August 2022. The Cochrane scoring system was used to assess the methodological quality of the included randomized trials. Five studies were reviewed and included in this analysis. Dapagliflozin at a dose of 5 to 10 mg was utilized in adolescents and young adults with heart failure, chronic kidney disease with proteinuria, type 1 diabetes, or type 2 diabetes. Studies evaluating dapagliflozin in type 1 diabetes evaluated single doses while the other studies monitored long-term use. Dapagliflozin was overall considered to be safe and effective in the studies included in this review, but further studies in larger populations and over extended periods of time are necessary.